340B Health

340B Insight Podcast

340B Insight

340B Insight is 340B Health’s podcast, providing our members and supporters with timely news updates and discussion around the 340B drug pricing program. The podcast enables listeners to stay current and expand their knowledge of 340B to help them serve their patients and communities and remain compliant with rules and requirements. New episodes are published twice per month and include news update segments and in-depth interviews with leading experts including health care practitioners, policy and legal experts, public policymakers, and our expert staff.

Listen and Subscribe

Have a question or suggestion for 340B Insight? Email us at: podcast@340bhealth.org

Follow 340B Health on Twitter, Facebook, and LinkedIn



  • Episode Two: The State of 340B During COVID-19 with Maureen Testoni

    In this episode, we speak with our President and CEO, Maureen Testoni, about the impact of COVID-19 on the 340B program. Maureen also discusses other key issues for the 340B community amid the uncertainty of the pandemic. (Transcript)

    Read more

  • Episode One: HRSA’s OPA Response to COVID-19 with Rear Admiral Krista Pedley

    The inaugural episode of 340B Insight features 340B Health President and CEO Maureen Testoni interviewing Rear Admiral Krista M. Pedley, the Director of the Office of Pharmacy Affairs (OPA) in the Health Resources & Services Administration (HRSA). OPA administers the 340B drug pricing program. Rear Admiral Pedley offers numerous insights into critical 340B issues, including HRSA Provides Flexibility During the COVID-19 Pandemic. (Transcript)

    Read more

  • Trailer: Introducing 340B Insight

    Welcome to 340B Insight! Hosted by 340B Health, the nation’s leading advocate for hospitals participating in the 340B drug pricing program. 340B Insight features the latest news, expert interviews, and answers to your questions. Learn about the ways 340B hospitals use program savings, demonstrate patient health improvements, respond to public health emergencies, and more.

    Read more